CN119630646A - Tead靶向化合物及其方法 - Google Patents

Tead靶向化合物及其方法 Download PDF

Info

Publication number
CN119630646A
CN119630646A CN202380054759.5A CN202380054759A CN119630646A CN 119630646 A CN119630646 A CN 119630646A CN 202380054759 A CN202380054759 A CN 202380054759A CN 119630646 A CN119630646 A CN 119630646A
Authority
CN
China
Prior art keywords
compound
optionally substituted
formula
cancer
tead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380054759.5A
Other languages
English (en)
Chinese (zh)
Inventor
卓德韦
洪万进
R·库马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of CN119630646A publication Critical patent/CN119630646A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202380054759.5A 2022-05-20 2023-03-28 Tead靶向化合物及其方法 Pending CN119630646A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202205354V 2022-05-20
SG10202205354V 2022-05-20
PCT/SG2023/050202 WO2023224545A2 (en) 2022-05-20 2023-03-28 Tead targeting compounds and methods thereof

Publications (1)

Publication Number Publication Date
CN119630646A true CN119630646A (zh) 2025-03-14

Family

ID=88836293

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380054759.5A Pending CN119630646A (zh) 2022-05-20 2023-03-28 Tead靶向化合物及其方法

Country Status (5)

Country Link
US (1) US20250197355A1 (https=)
EP (1) EP4526295A4 (https=)
JP (1) JP2025517442A (https=)
CN (1) CN119630646A (https=)
WO (1) WO2023224545A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188239A1 (en) * 2024-03-05 2025-09-12 Agency For Science, Technology And Research Pan-tead inhibitors and methods thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053706A1 (en) * 2015-09-23 2017-03-30 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
EP3866798A4 (en) * 2018-10-15 2022-07-13 Dana-Farber Cancer Institute, Inc. ENHANCED TRANSCRIPTIONAL ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES

Also Published As

Publication number Publication date
EP4526295A2 (en) 2025-03-26
EP4526295A4 (en) 2026-05-06
WO2023224545A2 (en) 2023-11-23
JP2025517442A (ja) 2025-06-05
US20250197355A1 (en) 2025-06-19
WO2023224545A3 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
Zhang et al. Polo-like kinase 1 inhibitors in human cancer therapy: development and therapeutic potential
Li et al. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
Zhang et al. Histone deacetylase inhibitors FK228, N‐(2‐aminophenyl)‐4‐[N‐(pyridin‐3‐yl‐methoxycarbonyl) amino‐methyl] benzamide and m‐carboxycinnamic acid bis‐hydroxamide augment radiation‐induced cell death in gastrointestinal adenocarcinoma cells
Lee et al. Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor
CN103635187B (zh) 用于抑制化疗引起的副作用的药物治疗以及相关药物组合物、诊断试剂、筛选技术和试剂盒
US20130317101A1 (en) Singleton inhibitors of sumoylation enzymes and methods for their use
US12496302B2 (en) Compositions and methods for the treatment and diagnosis of cancer
CN112638889A (zh) 用于治疗的尿石素a和其衍生物
US9533969B2 (en) Materials and method for inhibiting replication protein A and uses thereof
KR20210113162A (ko) Kras 종양유전자 활성화의 억제를 위한 플라배글린 유도체
CN103476411B (zh) 标靶人类胸腺核苷酸激酶诱导恶性肿瘤中的dna修复毒性
CN119630646A (zh) Tead靶向化合物及其方法
Durrant et al. Targeted inhibition of phosphoinositide 3-kinase/mammalian target of rapamycin sensitizes pancreatic cancer cells to doxorubicin without exacerbating cardiac toxicity
WO2012149452A1 (en) Compounds, formulations, and methods of protein kinase c inhibition
US20110275596A1 (en) Methods for treating neoplasia and for identifying compositions useful in such therapy
JP7138975B2 (ja) 新生物障害及び神経性障害の診断、治療及び予防のための組成物及び方法
US8293764B2 (en) Compositions and methods for disruption of BRCA2-Rad51 interaction
US20230201168A1 (en) New therapy for the treatment of tumors
US8772321B2 (en) Heteroannelated anthraquinone derivatives for inhibiting cancers
US10512631B2 (en) Chalcone compounds
US20200061054A1 (en) Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a parp inhibitor
WO2025188239A1 (en) Pan-tead inhibitors and methods thereof
HK40029376A (en) Drug therapy to inhibit chemotherapy-induced adverse effects and screening techniques and kits
US20200046654A1 (en) Bupropion and pharmaceutical composition for treating cancer and method for inhibiting migration of tumor cells
HK40029376B (en) Drug therapy to inhibit chemotherapy-induced adverse effects and screening techniques and kits

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination